MAPK8

Across TCGA pan-cancer cohorts, MAPK8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK8 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAPK8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAPK8 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where MAPK8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.873	0.413	<.001	97	view →
LSCC	OS	Tertile	All	0.715	0.942	.003	23	view →
LUAD	OS	Tertile	II,III,IV	0.249	0.682	.007	15	view →
PDAC	OS	Quartile	All	0.341	0.578	.004	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPK8–CCRCC (OS)

Open the CCRCC breakdown →